STAGE IV UVEAL MELANOMA AJCC V7
Clinical trials for STAGE IV UVEAL MELANOMA AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV UVEAL MELANOMA AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IV UVEAL MELANOMA AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for rare eye cancer
Disease control OngoingThis study tests two treatments for uveal melanoma that has spread. One group gets trametinib alone, the other gets trametinib plus GSK2141795. The goal is to see which slows tumor growth better. About 42 adults with advanced disease are taking part.
Matched conditions: STAGE IV UVEAL MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug trial targets rare eye cancer that spreads
Disease control OngoingThis study tests a drug called vorinostat in 40 people with uveal melanoma that has spread to other parts of the body. The drug works by blocking enzymes that help cancer cells grow. The goal is to see if it can shrink tumors and help people live longer.
Matched conditions: STAGE IV UVEAL MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:02 UTC